Investments & digital assets › F8949.D.X17
F8949.D.X17 · federal · F8949 line D.X17
Delmar Pharma (acquired 2024-02-22, sold 2025-08-25; proceeds 1,680.45, basis 1,816.05)
-135.60
engine v3
not yet verified
How this number was built
R-8949-LOT One line per sale: proceeds minus basis plus adjustment. Broker basis is used as reported unless a supplemental statement for the same lot is matched.
Sources (6) — where the inputs came from
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 17 · field X17_desc · “Lot X17 description”
read as “Delmar Pharma” → Delmar Pharma
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 17 · field X17_acq · “Lot X17 date acquired”
read as “02/22/2024” → 2024-02-22
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 17 · field X17_sold · “Lot X17 date sold”
read as “08/25/2025” → 2025-08-25
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 17 · field X17_proceeds · “Lot X17 proceeds”
read as “1,680.45” → 1,680.45
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 17 · field X17_basis · “Lot X17 cost basis”
read as “1,816.05” → 1,816.05
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 17 · field X17_wash · “Lot X17 wash sale loss disallowed”
read as “0.00” → 0
99%
Flows into
History — nothing is overwritten
v1 · 2026-03-04: -135.60v2 · 2026-03-19: -135.60v3 · 2026-06-23: -135.60
Adjust this number
Evidence & discussion
Record how you verified it